
Shinji Urakami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8978249/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. Anticancer Research, 2020, 40, 5295-5299.	O.5	6
2	Macroscopic hematuria caused by runningâ€induced traumatic bladder mucosal contusions. IJU Case Reports, 2019, 2, 27-29.	0.1	5
3	Effect of tadalafil addâ€on therapy in patients with persistant storage symptoms refractory to α ₁ â€adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 109-114.	0.6	6
4	Recent advances in medical therapy for metastatic urothelial cancer. International Journal of Clinical Oncology, 2018, 23, 599-607.	1.0	30
5	Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. International Journal of Urology, 2018, 25, 151-156.	0.5	29
6	Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. International Journal of Urology, 2016, 23, 158-159.	0.5	0
7	Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. International Journal of Clinical Oncology, 2015, 20, 1198-1202.	1.0	1
8	Patient-perceived Satisfaction After Definitive Treatment for Men With High-risk Prostate Cancer: Radical Prostatectomy vs Intensity-modulated Radiotherapy With Androgen Deprivation Therapy. Urology, 2015, 85, 407-414.	0.5	12
9	Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. International Journal of Clinical Oncology, 2015, 20, 1171-1178.	1.0	22
10	Decreased incidence of skeletal-related events in mRCC. Nature Reviews Urology, 2014, 11, 193-194.	1.9	6
11	The Processus Vaginalis Transection Method to Prevent Postradical Prostatectomy Inguinal Hernia: Long-term Results. Urology, 2014, 83, 247-252.	0.5	16
12	Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 35.e1-35.e7.	0.8	3
13	Significance of zoledronic acid on survival in patients with bone metastases from renal cell carcinoma Journal of Clinical Oncology, 2013, 31, 374-374.	0.8	Ο
14	Impact of Câ€reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by secondâ€line chemotherapy with gemcitabine, etoposide and cisplatin. BJU International, 2012, 110, 1478-1484.	1.3	28
15	Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml. Urologia Internationalis, 2011, 87, 175-181.	0.6	5
16	Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. International Urology and Nephrology, 2008, 40, 365-368.	0.6	8
17	WS1-1-2 Wnt-antagonist Family Genes as Biomarkers for Diagnosis, Staging and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA(Renal Cell Cancer). Japanese Journal of Urology, 2008, 99, 142.	0.0	0
18	Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer. European Urology, 2007, 51, 1252-1258.	0.9	25

Shinji Urakami

#	Article	IF	CITATIONS
19	Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy. Clinical Cancer Research, 2006, 12, 6116-6124.	3.2	142
20	Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study. Urology, 2005, 65, 543-548.	0.5	22
21	Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate Cancer. Journal of Urology, 2002, 168, 2444-2450.	0.2	64
22	Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. Journal of Urology, 2002, 168, 2444-50.	0.2	17